PRNewsWire
10 Aug 2026, 09:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
ARS Pharmaceuticals is facing a securities fraud class action lawsuit alleging false and misleading statements regarding the commercialization of its product, neffy. — Securities litigation creates legal liability risks and damages investor confidence in management's transparency.
-0.60The lawsuit claims ARS disregarded timeline risks regarding the addition of neffy to CVS Caremark's formulary. — Formulary placement is a critical driver of revenue for pharmaceutical products; delays or failures here directly impact sales forecasts.
-0.50Which stocks this story touches
The company is facing a securities fraud class action lawsuit alleging false and misleading statements regarding insurance coverage timelines.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
